肥胖的绝经后乳腺癌患者使用芳香化酶抑制剂不被支持

        最近的数据提示，芳香化酶抑制剂用于超重和/或肥胖乳腺癌患者可能有临床疗效。该项研究报道了乳腺癌患者经不同芳香化酶抑制剂治疗后身体质量指数（BMI）相关的体内芳香化酶抑制剂、血浆和组织雌激素水平。

        挪威Haukeland大学的Lønning日前发表在European Journal of Cancer杂志上的一项研究显示，在芳香化酶治疗前和治疗期间超重的绝经后乳腺癌患者雌激素水平的升高可能是由于BMI对雌激素代谢的影响，而非芳构化。因而不支持超重患者或因此需替代疗法的患者人群使用芳香化酶抑制剂治疗。

        研究者还对体内芳香化酶抑制剂（64例患者）以及受试患者的血浆和组织雌激素水平与BMI值进行了比较。研究者发现，治疗前患者的芳构化水平与BMI指数呈弱正相关，但在任一芳香化酶抑制剂方案治疗亚组，患者治疗期间的芳构化水平或芳香化酶抑制剂水平与BMI无相关。治疗前血浆雌二醇、雌酮、和雌酮硫酸盐水平与患者BMI相关。

        而对于接受来曲唑、或阿那曲唑治疗中的患者血浆雌酮硫酸盐水平与BMI相关，来曲唑抑制血浆雌酮硫酸盐的效应超过阿那曲唑，且此效应独立于BMI。未见治疗中肿瘤组织雌激素水平与BMI指数相关的报道。

        从本研究独特的数据结果来看，不支持超重患者或因此需替代疗法的患者人群使用芳香化酶抑制剂治疗。在芳香化酶治疗前和治疗期间超重的绝经后乳腺癌患者雌激素水平的升高可能是由于BMI对雌激素代谢的影响，而非芳构化。

你这个翻译不行，标题就错，意思完全就相反，
原文在这里

http://www.docguide.com/relation ... nopausal-bre?tsid=5

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors; Lønning P, Haynes B, Dowsett M; European Journal of Cancer (Feb 2014)
Tags: Breast Cancer Menopause Obesity
Read/Add Comments | Email This | Print This | PubMed | Get Full Text
BACKGROUND Recent data have raised concern about the clinical efficacy of aromatase inhibitors in overweight and/or obese breast cancer patients. We report in vivo aromatase inhibition and plasma and tissue oestrogen levels in relation to body mass index (BMI) status among breast cancer patients treated with different aromatase inhibitors.

METHODS We compared data on in vivo aromatase inhibition (64 patients) as well as plasma and tissue oestrogen levels from patients participating in our studies to BMI values.

RESULTS We found a weak positive correlation between pretreatment aromatisation level and BMI (n=64; R=0.236; p=0.060) but no correlation between on-treatment aromatisation levels or percentage aromatase inhibition and BMI within patient subgroups treated with any of a panel of aromatase inhibitors. Pre-treatment levels of plasma estradiol (p<0.001), estrone (p=0.001) and estrone sulphate (p=0.002) correlated to BMI. While on-treatment levels of plasma estrane sulphate correlated to BMI in patients on letrozole (R=0.601; p=0.001; n=25 for all) or anastrozole (n=12; R=0.611; p=0.035) therapy, letrozole suppressed plasma estrone sulphate more than anastrozole independent of BMI. No correlation between on-treatment tumour oestrogen levels and BMI was recorded.

CONCLUSIONS Our unique data do not support a lack of effective aromatase inhibition in overweight patients or therefore a need for alternative therapy. The higher levels of estrogens in overweight postmenopausal breast cancer patients before and during aromatase inhibition may be due to effects of BMI on oestrogen metabolism rather than aromatisation.


注意红字，直译就是研究数据不支持芳香化酶抑制剂在超重病人身上缺乏效果。

就是说芳香化酶抑制在超重病人身上是有效的。超重病人雌激素高可能是因为超重有关的雌激素代谢过于芳香化作用。

另外治疗期间肿瘤雌激素水平跟BMI没关系。

seacat 发表于 2014-3-26 19:30
你这个翻译不行，标题就错，意思完全就相反，
原文在这里

不好意思，我参照的是丁香园上的一篇中文报道，呵呵~
http://oncol.dxy.cn/article/70680?trace=dxk

CONCLUSIONS Our unique data do not support a lack of effective aromatase inhibition in overweight patients or therefore a need for alternative therapy. The higher levels of estrogens in overweight postmenopausal breast cancer patients before and during aromatase inhibition may be due to effects of BMI on oestrogen metabolism rather than aromatisation.


我的理解是：我们的研究数据不支持，超重患者缺乏有效的芳香化酶抑制剂。。。在AI治疗前或治疗期间，超重的绝经后乳腺癌患者的高水平雌激素，可能是由于BMI对雌激素的代谢作用，而不是aromatisation。